Effect of Esaxerenone, a novel mineralocorticoid receptor antagonist on insulin resistance in diabetic patients with hypertension.

Effect of Esaxerenone, a novel mineralocorticoid receptor antagonist on insulin resistance in diabetic patients with hypertension. - Effect of Esaxerenone, a novel mineralocorticoid receptor antagonist on insulin resistance in diabetic patients with hypertension.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041326

Enrollment

Registered

2020-09-01

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus with hypertension

Interventions

Esaxerenone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients with type 2 diabetes and hypertension, who are treated with ACE inhibitor or angiotensin II receptor blocker.

Exclusion criteria

Exclusion criteria: 1. Patients treated with insulin 2. Patients treated with steroid 3. Patients with renal disfunction(eGFR<60) 4. Patients with hyperkalemia(K>5.0mEq/L) 5. Pregnant or nursing patients

Design outcomes

Primary

Measure	Time frame
Changes in M/I ratio from baseline at 6 months	—

Countries

Japan

Contacts

Public ContactMotoyuki Igata

Faculty of Life Sciences, Kumamoto University Department of Metabolic Medicine

iga@gpo.kumamoto-u.ac.jp0963735169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026